A Study to Evaluate the Safety and Efficacy of Celgosivir in Patients With Chronic Hepatitis C Genotype 1 Infection

A Phase II, Randomised, Dose-Ranging, Open-Label, Multi-Centre Study to Evaluate the Safety and Efficacy of Celgosivir for 12 Weeks in Patients With Chronic Hepatitis C Infection

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00157534

Enrollment

Registered

2005-09-12

Start date

2004-10-31

Completion date

2005-08-31

Last updated

2005-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C, Chronic

Keywords

Hepatitis C, Celgosivir, HCV, Genotype 1

Brief summary

The objective of the study is to evaluate the safety and efficacy of celgosivir for 12 weeks in patients with chronic hepatitis C genotype 1 infection.

Interventions

DRUGCelgosivir

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* The patient must be 18 to 65 years of age, inclusive. * Primary diagnosis of chronic HCV infection.

Exclusion criteria

* Patients who did not respond or relapsed following therapy with interferon.

Design outcomes

Primary

Measure	Time frame
Safety analysis	—

Secondary

Measure	Time frame
Hepatitis C viral load	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026